{"filing":{"accession_number":"0001213900-26-085434","cik":"0001851484","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ea0300371-8k_citius.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026085434/ea0300371-8k_citius.htm"},"events":[{"id":24785,"run_id":22475,"accession_number":"0001213900-26-085434","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses a commercial progress update on LYMPHIR's institutional adoption and market access, including a 78% quarter-over-quarter increase in new institutional accounts ordering the product, expansion to 42 institutions, and near-universal payer coverage. While this is a positive operational/commercial milestone for the company's recently launched oncology product (approved December 2025), it does not fit neatly into the specific event categories (e.g., earnings_release, which typically reports full financial results; operational_other best captures this strategic commercial update). The disclosure is material to investors assessing the company's commercial execution and revenue trajectory for LYMPHIR.","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25457,"accession_number":"0001213900-26-085434","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a commercial progress update on LYMPHIR's institutional adoption and market access, including a 78% quarter-over-quarter increase in new institutional accounts ordering the product, expansion to 42 institutions, and near-universal payer coverage. While this is a positive operational/commercial milestone for the company's recently launched oncology product (approved December 2025), it does not fit neatly into the specific event categories (e.g., earnings_release, which typically reports full financial results; operational_other best captures this strategic commercial update). The disclosure is material to investors assessing the company's commercial execution and revenue trajectory for LYMPHIR.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:21:33.758231+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25457,"accession_number":"0001213900-26-085434","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a commercial progress update on LYMPHIR's institutional adoption and market access, including a 78% quarter-over-quarter increase in new institutional accounts ordering the product, expansion to 42 institutions, and near-universal payer coverage. While this is a positive operational/commercial milestone for the company's recently launched oncology product (approved December 2025), it does not fit neatly into the specific event categories (e.g., earnings_release, which typically reports full financial results; operational_other best captures this strategic commercial update). The disclosure is material to investors assessing the company's commercial execution and revenue trajectory for LYMPHIR.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:21:33.758231+00:00","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-08-05"}]}